435 related articles for article (PubMed ID: 12558337)
1. Epidemiology of measles, mumps and rubella in Italy.
Gabutti G; Rota MC; Salmaso S; Bruzzone BM; Bella A; Crovari P;
Epidemiol Infect; 2002 Dec; 129(3):543-50. PubMed ID: 12558337
[TBL] [Abstract][Full Text] [Related]
2. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
3. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
4. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy.
Ciofi Degli Atti ML; Salmaso S; Bella A; Arigliani R; Gangemi M; Chiamenti G; Brusoni G; Tozzi AE;
Pediatr Infect Dis J; 2002 Aug; 21(8):763-8. PubMed ID: 12192166
[TBL] [Abstract][Full Text] [Related]
5. Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry.
Ramondetti F; Sacco S; Comelli M; Bruno G; Falorni A; Iannilli A; d'Annunzio G; Iafusco D; Songini M; Toni S; Cherubini V; Carle F;
Diabet Med; 2012 Jun; 29(6):761-6. PubMed ID: 22133003
[TBL] [Abstract][Full Text] [Related]
6. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001.
Choe YJ; Eom HE; Cho SI
J Med Virol; 2017 Sep; 89(9):1528-1531. PubMed ID: 28303592
[TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, September 2016 to July 2018.
Andrianou XD; Del Manso M; Bella A; Vescio MF; Baggieri M; Rota MC; Pezzotti P; Filia A
Euro Surveill; 2019 Apr; 24(17):. PubMed ID: 31039836
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
[TBL] [Abstract][Full Text] [Related]
9. Surveillance and vaccination coverage of measles and rubella in Northern Italy.
Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A
Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
[TBL] [Abstract][Full Text] [Related]
11. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
12. Measles, mumps, rubella prevention: how can we do better?
Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
[TBL] [Abstract][Full Text] [Related]
14. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies.
Edmunds WJ; Gay NJ; Kretzschmar M; Pebody RG; Wachmann H;
Epidemiol Infect; 2000 Dec; 125(3):635-50. PubMed ID: 11218214
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
Mossong J; Putz L; Schneider F
Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082
[TBL] [Abstract][Full Text] [Related]
17. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
Amela C; Pachón I; de Ory F
Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
[TBL] [Abstract][Full Text] [Related]
19. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?
Cameron NA
Vaccine; 2012 Sep; 30 Suppl 3():C58-60. PubMed ID: 22939023
[TBL] [Abstract][Full Text] [Related]
20. Utility of serological screening for measles, mumps and rubella in immunocompromised patients.
Sticchi L; Astengo M; Iavarone IG; Icardi G
Hum Vaccin Immunother; 2019; 15(12):2854-2855. PubMed ID: 31442102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
